BioAge Labs, Inc. (BIOA)
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
BioAge Labs Inc.
NASDAQ:BIOAHealthcare · Biotechnology
-1.18%$5.87
AH$5.87+0.00%vs close
Mkt Cap$269.41M
Float40.8M
O/S45.9M
Vol
$ Vol
RVOL
Inst Own82.9%
SI8.4%
Earnings
Dilution
Financials Summary
Revenue$8.99M
Net Income-$80.61M
Total Assets$294.89M
Free Cash Flow-$82.35M
Debt & Equity
Debt 2%
Equity 98%
Total Debt$5.56M
Total Equity$272.05M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in BIOA's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$294.89M
Liabilities$22.84M
Accounts Receivable$769K
Accounts Payable$2.67M
Inventory$0
PP&E (Net)$3.75M
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Currency | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
| Revenue | $8.99M | $0 | $0 | $0 |
| YoY Growth | - | - | - | - |
| Cost of Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $8.99M | $0 | $0 | $0 |
| Gross Margin | 100.0% | - | - | - |
| Research and Development | $73.97M | $59.04M | $33.89M | $30.52M |
| Selling, General, and Administrative | $27.81M | $19.16M | $14.51M | $9.45M |
| Other | $0 | $0 | $0 | $0 |
| Total Operating Expenses | $101.78M | $78.19M | $48.4M | $39.97M |
| Operating Income (EBIT) | -$92.78M | -$78.19M | -$48.4M | -$39.97M |
| Operating Margin | -1031.5% | - | - | - |
| Interest Expense | $697K | $2.37M | $7.79M | $241K |
| Interest Income | $13.09M | $9.63M | $2.43M | $465K |
| Other Income (Expense) | $12.18M | $7.08M | -$15.45M | $247K |
| Income Before Tax (EBT) | -$80.61M | -$71.11M | -$63.85M | -$39.72M |
| Income Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$80.61M | -$71.11M | -$63.85M | -$39.72M |
| Net Income Margin | -896.1% | - | - | - |
| Supplementary Data | ||||
| EPS | -2.24 | -1.98 | -1.87 | -1.16 |
| Diluted EPS | -2.24 | -1.98 | -1.87 | -1.16 |
| Weighted Average OS | 35.93M | 35.85M | 34.20M | 34.17M |
| EBITDA | -$79.69M | -$68.58M | -$55.9M | -$39.35M |
| EBITDA Margin | -886.0% | - | - | - |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Currency | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
| Assets | ||||
| Current Assets | ||||
| Cash and Cash Equivalents | $188.89M | $354.35M | $21.64M | $27.64M |
| Short-Term Investments | $92.21M | $0 | $0 | $0 |
| Cash and Short-Term Investments | $281.1M | $354.35M | $21.64M | $27.64M |
| Accounts Receivable | $769K | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Current Assets | $4.93M | $2.75M | $3.66M | $386K |
| Total Current Assets | $286.79M | $357.1M | $25.31M | $28.03M |
| Long-Term Assets | ||||
| Property, Plant & Equipment Net | $3.75M | $791K | $518K | $374K |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 |
| Long-Term Investments | $100K | $100K | $100K | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $4.25M | $240K | $0 | $25K |
| Total Long-Term Assets | $8.1M | $1.13M | $618K | $399K |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $294.89M | $358.23M | $25.92M | $28.43M |
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts Payable | $2.67M | $2M | $1.87M | $2.26M |
| Short-Term Debt | $2.65M | $6M | $44.86M | $167K |
| Current Income Tax Payable | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $5.75M | $7.83M | $3.31M | $0 |
| Other Current Liabilities | $525K | $417K | $1.39M | $24K |
| Total Current Liabilities | $20.14M | $27.77M | $58.17M | $5.86M |
| Long-Term Liabilities | ||||
| Long-Term Debt | $2.33M | $2.5M | $8.2M | $2.25M |
| Long-Term Unearned Revenue | $0 | $4.67M | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $370K | $156K | $132.95M | $132.88M |
| Total Long-Term Liabilities | $2.7M | $7.33M | $141.15M | $135.13M |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Total Liabilities | $22.84M | $35.11M | $199.32M | $140.99M |
| Stockholders' Equity | ||||
| Preferred Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$333.42M | -$252.81M | -$181.7M | -$117.85M |
| Comprehensive Income & Other | $278K | $245K | $164K | $167K |
| Other Stockholders' Equity | $605.47M | $575.94M | $8.31M | $5.29M |
| Total Equity | $272.05M | $323.13M | -$173.4M | -$112.56M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $294.89M | $358.23M | $25.92M | $28.43M |
| Supplementary Data | ||||
| Total Debt | $5.56M | $8.7M | $53.25M | $2.47M |
| Net Debt | -$183.33M | -$345.64M | $31.61M | -$25.18M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Currency | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
| Operating Activities | ||||
| Net Income | -$80.61M | -$71.11M | -$63.85M | -$39.72M |
| Depreciation & Amortization | $213K | $167K | $162K | $129K |
| Deferred Income Tax | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $11.69M | $6.98M | $3.02M | $2.54M |
| Changes in Working Capital: | ||||
| Accounts Receivable | -$769K | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Accounts Payable | $788K | $6K | -$393K | $994K |
| Other Working Capital | -$11.85M | $11.17M | $7.1M | -$199K |
| Total Working Capital Change | -$11.83M | $11.18M | $6.71M | $795K |
| Other Non-Cash Items | -$1.1M | $1.26M | $16.6M | $77K |
| Net Cash from Operating | -$81.63M | -$51.52M | -$37.36M | -$36.18M |
| Investing Activities | ||||
| Capital Expenditures | -$719K | -$366K | -$166K | -$103K |
| Acquisitions | $0 | $0 | $0 | $0 |
| Purchases of Investments | -$154.75M | $0 | -$100K | $0 |
| Sales of Investments | $60.25M | $0 | $0 | $0 |
| Other Investing Activities | $0 | $0 | $0 | $0 |
| Net Cash from Investing | -$95.22M | -$366K | -$266K | -$103K |
| Financing Activities | ||||
| Debt Repaid | $6M | $6M | -$11.5M | -$2.5M |
| Common Stock Issuance | $17.87M | $221.62M | $0 | $44K |
| Common Stock Repurchases | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Financing Activities | -$400K | -$4.42M | -$59K | -$45K |
| Net Cash from Financing | $11.47M | $381.2M | $34.94M | $2.5M |
| Forex Effect | -$87K | $81K | $0 | $246K |
| Net Change in Cash | -$165.46M | $329.39M | -$2.69M | -$33.54M |
| Supplementary Data | ||||
| Operating Cash Flow | -$81.63M | -$51.52M | -$37.36M | -$36.18M |
| Capital Expenditure | -$719K | -$366K | -$166K | -$103K |
| Free Cash Flow | -$82.35M | -$51.89M | -$37.53M | -$36.28M |
| Cash at Beginning | $354.35M | $24.96M | $27.64M | $61.18M |
| Cash at End | $188.89M | $354.35M | $24.96M | $27.64M |